SCENE / NAD+ & AGING
NAD and Aging in the Research Literature: Reading the NAD+ Decline
Tissue NAD+ falls with age. This scene reads why the decline happens, which enzymes drive it, and what precursor research has and has not shown.
In plain English
As you get older, the amount of NAD+ (a fuel-handling helper molecule every cell uses to make energy) inside your tissues slowly drops. Part of the reason is an enzyme called CD38 that burns NAD+ and becomes more active with age, so the cell spends NAD+ faster than it can rebuild it. This page — about NAD and aging — walks through what the studies have shown about that decline, and why researchers test precursors (building blocks like NMN and NR) to try to push NAD+ back up. It describes findings only; it is not advice to take anything.
Why tissue NAD+ falls with age
The age-related drop in NAD+ is not mainly a manufacturing failure — it is a consumption problem. CD38, an NAD-consuming ectoenzyme, rises with age and inflammation and is the principal driver of the fall in tissue NAD+ [2]. In mice, deleting CD38 preserves NAD+ levels and SIRT3 activity, protecting mitochondrial function and metabolic health into old age [2]. As NAD+ drops, sirtuins and PARPs — the other big consumers — compete harder for a shrinking pool, and nuclear-mitochondrial signaling can slip toward pseudohypoxia, a state in which the cell behaves as if starved of oxygen despite adequate supply [5].
Senescent cells make the problem self-reinforcing. The senescence-associated secretory phenotype (SASP) — the inflammatory signals aging cells release — drives CD38 expression in tissue macrophages, creating a feedback loop that depletes NAD+ further [14]. A 2024 review proposed pairing NAD-boosting strategies with senolytics (drugs that clear senescent cells) as a complementary approach in animal models [14]. This is mechanism, not a treatment claim.
What precursor research has shown about the decline
If the decline is real, can raising NAD+ reverse its consequences? In animals, the signal is consistent. A 2024 critical review of NMN's anti-aging mechanisms identified four core pathways — cellular energy metabolism, apoptosis inhibition, immune modulation, and genomic stability — and documented NMN activating sirtuins while reducing CD38 and PARP-1 activity in aged tissue [15]. NMN supplementation reduced markers of cellular senescence in aged mice [14].
In humans the picture is narrower but not empty. NMN dose-dependently raised blood NAD+ over 60 days and improved walking distance in middle-aged adults [3], and 10 weeks of NMN improved muscle insulin sensitivity in prediabetic postmenopausal women [1]. What no human study shows is reversal of aging itself: a 2025 Nature Metabolism review concluded that age-related NAD+ decline has been confirmed in only a limited number of human studies and that human efficacy for clinical endpoints remains preliminary [13]. The strongest anti-aging data are still rodent data, and that gap is the honest center of this scene.
Caution: context-dependence and the cancer question
Raising NAD+ is not uniformly benign in theory. NAMPT-driven NAD+ metabolism governs the proinflammatory SASP independently of growth arrest, and the authors of that work cautioned that NAD+ augmentation should be applied with precision in aging populations [8]. Separately, because NAD+ supports the metabolism of proliferating cells, a theoretical concern exists that boosting it could fuel existing cancers; NAD+ has dual, context-dependent roles in oncology, so caution is advised in cancer populations [13]. These are research caveats reported in the literature, not predictions about any individual, and this page makes no clinical recommendation.